Drug Trial Radar · NCT07901725
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
382
Planned (sponsor's estimate)
Start
Dec 18, 2026
Primary completion
Jul 25, 2035
Study completion Jul 25, 2035
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can help treat participants who are newly diagnosed and previously untreated for systemic amyloid light-chain (AL) amyloidosis. The aim of this study is to see if the safety and efficacy of linvoseltamab alone can deliver better disease control and outcomes than Dara-VCd. The study is looking at: * What side effects linvoseltamab alone might cause * How well linvoseltamab works compared to Dara-VCd regimen in terms of reductions of the abnormal proteins that cause AL-amyloidosis that affects the heart and kidney functions and for how long * How much linvoseltamab is in the blood at different times * Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects)
Conditions
- Newly Diagnosed Amyloidosis
- Amyloidosis Stage I-IIIA
Interventions
LinvoseltamabDrug
Administered per the protocol
DaratumumabDrug
Administered per the protocol
BortezomibDrug
Administered per the protocol
CyclophosphamideDrug
Administered per the protocol
DexamethasoneDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 7 years
- Severity of TEAEsTime frame: Up to 7 years
- Occurrence of Adverse Events of Special Interest (AESI)Time frame: Up to 7 years
- Severity of AESITime frame: Up to 7 years
- Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 7 years
- Severity of SAEsTime frame: Up to 7 years
- Achievement of Hematologic Complete Response (HemCR) per International Society of Amyloidosis (ISA) response criteria as determined by Blinded Independent Review Committee (BIRC)Time frame: Up to 7 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.